I’ve been writing and editing technology articles for more than seven years, most recently as part of PCMag's software team. I am responsible for content in the AI, financial, graphic design, ...

Why the current system is broken and what local governments, nonprofits, and philanthropists could do to change it.

Q3 2025 Earnings Call Transcript November 4, 2025 Corcept Therapeutics Incorporated misses on earnings expectations. Reported ...

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results cons ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory ...

Introduction Although there are some drugs to control Parkinson’s disease (PD), they have several side effects and cannot ...

Cash and Cash Equivalents: As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash ...